27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Concordance between p-tau217 and Aβ was high in the AD and MCI groups (observed agreement 90.0% in each), but overall agreement across Cohort II was modest (166/351, 47.3%; Cohen's κ = 0.117, 95% CI 0.029–0.204). 3 key findings →
Design: longitudinal study Participants: 918 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Test-retest reliability measures are essential for interpretation of meaningful effects over time for plasma and digital outcomes. 1 key finding →
Participants: 92 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Frontotemporal lobar degeneration (FTLD), predominantly comprised of tau and TDP-43 proteinopathies, is a common cause of early-onset dementia. 3 key findings →
Participants: 566 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study provides quantitative evidence supporting the complementary use of multiple cognitive assessment tools. 4 key findings →
Design: cross-sectional Participants: 250 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia affects more than 55 million people worldwide, and its progressive decline is difficult to track using infrequent in-person assessments, which can miss subtle changes between visits and add to clinician burden. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cognitive impairment is a prevalent symptom extending from physiological ageing to disease. 4 key findings →
Participants: 43 Evidence: low
Full summary, score breakdown and related studies → Original source
The Edinburgh Cognitive and Behavioral ALS Screen (ECAS) is the most validated and widely-used ALS-specific cognitive assessment tool, yet paper-and-pencil manual scoring introduces inter-rater variability that can significantly limit reliability and reproducibility in multi-site clinical trials. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Realising PCC in YOD requires not only identifying individual needs and appropriate care components, but also ongoing alignment of changing needs, expectations, timing, and responsibilities across the care trajectory. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Brain perfusion SPECT revealed AD-typical hypoperfusion patterns and demonstrated modest potential to estimate the presence or absence of Aβ deposition with left parietal rCBF. 5 key findings →
Participants: 88 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder, and early diagnosis is essential for timely intervention. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Accurate differential diagnosis between Alzheimer’s disease (AD) and frontotemporal dementia (FTD) is of critical importance for the early screening of neurodegenerative diseases. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Resting-state EEG is a scalable modality for neurophysiological screening, but conventional spectral descriptors capture only part of the signal organization altered in neurodegenerative disease. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
From 464 identified records, 30 peer-reviewed primary studies met all eligibility criteria following the exclusion of low-quality sources and unindexed preprints. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Biases in cognitive/functional screening tests may disproportionately exclude ethnoracial minorities in AD prevention trials. 1 key finding →
Participants: 6,669 Evidence: low
Full summary, score breakdown and related studies → Original source
Population ageing is accelerating globally, with a rising burden of neurocognitive disorders such as dementia and Alzheimer’s disease, particularly in low- and middle-income countries. 5 key findings →
Participants: 63 Evidence: low
Full summary, score breakdown and related studies → Original source
From 12,770 records, 3,636 duplicates were removed and 9,134 titles and abstracts were screened. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Most plasma proteomic studies in Alzheimer’s disease (AD) compare cases and controls cross-sectionally, leaving unresolved which AD-associated proteins mark diagnostic states and which are linked to disease progression. 5 key findings →
Design: longitudinal study Participants: 13,449 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Wearable devices repeatedly measure activity, sleep, and nocturnal physiology, but their value for three-class cognitive screening remains uncertain. 1 key finding →
Participants: 174 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia dyads experience substantial informational, emotional, and practical support needs in the early stages of MCI and AD/ADRD. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings provide evidence that age-related changes in the gut microbiota, particularly reductions in Bifidobacterium , partially mediate cognitive decline in older adults. 5 key findings →
Design: cross-sectional Participants: 578 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia with Lewy bodies (DLB) is a common neurodegenerative dementia that remains difficult to distinguish clinically from Alzheimer's disease (AD) and related disorders because of overlapping clinical features and frequent mixed pathology. 4 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is a widely prevalent neurodegenerative disorder characterized by progressive cognitive impairment and neuropathological alterations. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Synapse loss is the strongest pathological correlate of cognitive decline in Alzheimer’s disease, yet the molecular basis of synaptic vulnerability across disease progression remains poorly understood. 2 key findings →
Participants: 67 Evidence: low
Full summary, score breakdown and related studies → Original source
Neurotrophins regulate neuronal survival, differentiation, and synaptic plasticity through activation of tropomyosin receptor kinase (Trk) receptors, and their dysregulation is strongly implicated in neurodegenerative disorders, including Alzheimer’s disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a neurologic condition that is categorized by a progressive loss of neurons with time. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 1,775 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →